

Antibe Therapeutics Inc

15:17 10 Mar 2020

American Council on Science and Health hails Antibe's ATB-346 as potential breakthrough in pain med

The American Council on Science and Health (ACSH) hailed Antibe Therapeutics Inc's (CVE:ATE) (OTCMKTS:ATBPF) lead drug, ATB-346 as a potentially "much safer and possibly more effective option" for the treatment of chronic pain and inflammation than anything currently on the market.

The ACSH, a pro-science consumer advocacy organization, noted that Antibe is focused on developing safer, non-addictive drugs for pain management. The Toronto-based biotech is at the forefront of shaking up a \$11 billion industry with a revolutionary new product that provides the relief of opioids without the resulting gastrointestinal damage.

READ: Antibe Therapeutics enrolls last patient in Phase 2B dose-ranging study of lead drug ATB-346

A report in the ACSH journal noted that it has been "more than 120 years since heroin and aspirin were invented" and not much has changed. The mainstays of pain relief are still non-steroidal anti-inflammatory drugs (NSAIDs) and opioids.

"There hasn't been a material advance in the pharmacological treatment of pain since the 1890s, when heroin and aspirin were invented. That may change if an experimental drug being developed by a Toronto-based drug company keeps performing in advanced clinical trials," wrote Josh Bloom in American Council on Science and Health's publication on Tuesday.

"This could be huge," he added.

For short-term mild or moderate pain and inflammation, NSAIDs, such as Advil (ibuprofen) or Aleve (naproxen) are good, but some people can't take them at all, primarily because of gastrointestinal side effects. Long-term use can cause bleeding ulcers, even in people who don't suffer from heartburn-like symptoms.

Eliminates gastrointestinal side effects


Antibe is developing a naproxen-derivative that delivers pain relief without gastrointestinal damage, said the report.

"It was designed to also release small amounts of hydrogen sulfide, the poisonous gas from rotten eggs, upon decomposition. Best yet, the hydrogen sulfide isn't just coming along for the ride; it can also act as an anti-inflammatory agent. Two drugs for the price of one. Amazing."

Clearly, the hydrogen sulfide wasn't incorporated into ATB-346 by accident. "Endogenous gaseous mediators are involved in multiple cellular processes, including cell repair, inflammation, and smooth muscle tone," said the report.

Antibe is evaluating ATB-346 in Phase II clinical trials and it could be a much safer and effective option for the treatment of chronic pain and inflammation than anything we have now, added the report.

1 Year Share Price Graph



December 2019 May 2020 November 20

Share Information

Code: ATE
Listing: TSX-V
Sector: Pharma & Biotech
Website: antibethera.com

Company Synopsis:

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a \$20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention.

action@proactiveinvestors.com

Is it safe?

The Toronto-based biotech has the largest base of published animal and human data amassed for an NSAID-based drug, bigger than anything developed by Merck (NYSE:MRK), Pfizer (NYSE:PFE), Bayer AG (ETR:BAYN) or anyone else. They've built a game-changing drug platform, and are doing the science to prove it.

In a Phase IIb, double-blind gastrointestinal safety trial, ATB-346 was far superior to naproxen.

During a two-week treatment period, 53 out of 126 (42.1%) volunteers who got naproxen (500 mg, twice per day) developed ulcers while in the ATB-346 group (250 mg, once per day) 3 out of 118 (2.5%) people did.

On February 28, Antibe said that the last patient has been enrolled and is on treatment in the Phase 2B dose-ranging, efficacy study of Antibe's ATB-346. The study is evaluating the effectiveness of ATB-346 in reducing osteoarthritis pain compared to a placebo in 360 patients.

The company anticipates the release of top-line results within six weeks.

In addition to ATB-346, designed to target the need for a safer, non-addictive drug for chronic pain, Antibe's second pipeline drug ATB-352, targets the need for a non-addictive analgesic for treating post-surgical pain. ATB-340, meanwhile, is a GI-safe derivative of aspirin.

Contact the author Uttara Choudhury at uttara@proactiveinvestors.com

Follow her on Twitter: [@UttaraProactive](https://twitter.com/UttaraProactive)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).